Simtra BioPharma Solutions 启用印第安纳州布卢明顿逾2.5亿美元 H 楼,扩大无菌注射剂产能
Simtra BioPharma Solutions Opens $250 Million Building H to Expand Sterile Injectable Capacity in Bloomington
Simtra BioPharma Solutions 于2026年11月9日在印第安纳州布卢明顿启用逾2.5亿美元、15.3万平方英尺的 H 楼,新增预充式注射器、西林瓶及冻干能力。公司计划到2027年将美国及欧洲网络的灌装线从11条增至18条,并在德国哈雷/威斯特法伦及布卢明顿 Park 园区继续扩建。H 楼产线何时商业化生产及支持哪些客户项目尚未披露。
Simtra BioPharma Solutions has opened Building H, a 153,000-square-foot, $250 million-plus expansion in Bloomington, Indiana, that adds prefilled syringe, vial, and lyophilization capacity. The CDMO plans to grow from 11 to 18 filling lines across its US and European network by 2027.
Simtra BioPharma Solutions, a contract development and manufacturing organization (CDMO) focused exclusively on sterile injectables, opened Building H on November 9, 2026, a more than $250 million expansion of its manufacturing campus in Bloomington, Indiana.¹ The 153,000-square-foot facility adds prefilled syringe, vial, and lyophilization capabilities, expanding the range of sterile injectable products Simtra can support.¹
“Our customers are planning years ahead, and they need manufacturing partners that can do the same.” Ray Guidotti, chief operating officer, Simtra BioPharma Solutions
Indiana Governor Mike Braun and Bloomington Mayor Kerry Thomson joined company leaders, employees, and economic development officials at the ribbon-cutting ceremony.¹ Simtra expects the expansion to create hundreds of jobs in Bloomington.¹
“Building H represents much more than additional manufacturing capacity. It is an important milestone in the growth strategy we are executing across Simtra,” said Franco Negron, chief executive officer of Simtra BioPharma Solutions.¹ “We are investing in the capacity, technology and infrastructure our customers need to develop and manufacture increasingly complex sterile injectable medicines.”¹
How does Building H fit into Simtra’s broader expansion?
Building H is one piece of a multisite growth plan. Simtra has invested more than $125 million to expand manufacturing capacity in Halle/Westfalen, Germany, and has made an initial investment of more than $150 million at its new Bloomington Park Campus.¹ Across its US and European network, the company plans to grow from 11 filling lines to 18 by 2027.¹
The opening follows earlier steps at the Bloomington site. In October 2025, Simtra said it had added a flexible clinical line for prefilled syringes and liquid and lyophilized vials and was building a new production facility to house three isolator commercial-scale filling lines.² In a sponsored BioPharm International® video, Bo Watkins, senior vice president of sales and business management at Simtra, described the Bloomington expansions, including new syringe and vial lines and the site’s first high-potency filling line.
“Building H gives us significant new capacity in Bloomington today to go along with our expansion in Halle, while investment in our new Park campus creates additional options for the future,” said Ray Guidotti, chief operating officer of Simtra.¹ “Together, these investments give customers greater flexibility in where and how they manufacture and provide a foundation that can scale as their programs grow.”¹
Why is sterile fill-finish capacity in demand?
Growth in biologics, biosimilars, and GLP-1 therapies is driving demand for sterile drug products, and CDMOs are investing in fill-finish, lyophilization, inspection, and packaging capacity to keep pace.³ Prefilled syringes are a large part of that demand; one forecast projects the global prefilled syringe market will grow from $9.4 billion in 2026 to $20.3 billion by 2035.³
Sponsors are also outsourcing more of this work. A Research and Markets report cited increased outsourcing to CDMOs as an important driver of fill-finish market growth, reflecting sponsors’ need for specialized sterile manufacturing expertise and flexible production capacity.⁴ Grand View Research projects that the global sterile injectables CDMO market will grow from $41.6 billion in 2026 to $87.3 billion by 2033.⁴
That shift is changing what sponsors expect from manufacturing partners. In a BioPharm International video interview at BIO 2026, Kasper Øland, vice president of sales execution at Samsung Biologics, said, “Rather than treating CDMOs as supply chain vendors, companies increasingly expect a CDMO to function as an extension of their own operational team to ensure greater predictability, transparency, and timeline flexibility.”
What happens next?
With Building H open, Simtra’s next milestones are the continued buildout in Halle and at the Bloomington Park Campus as it works toward 18 filling lines by 2027.¹ The company has not disclosed when the new Building H lines will begin commercial production or which customer programs they will support.
“The facility combines advanced manufacturing technology with robust infrastructure to support the consistent, reliable supply of vital injectable products to our customers and their patients,” said Pat Adams, vice president of expansion operations at Simtra.¹
References
- Simtra BioPharma Solutions celebrates opening of $250+ million Bloomington manufacturing expansion. News release. Simtra BioPharma Solutions; November 9, 2026. Accessed November 19, 2026.
- Simtra BioPharma Solutions expands global manufacturing footprint to advance the future of sterile injectables. News release. Simtra BioPharma Solutions; October 27, 2025. Accessed November 19, 2026.
- Biologics push CMOs/CDMOs to expand sterile fill-finish and prefilled syringe capacity. BioSpace. Published August 3, 2026. Accessed November 19, 2026.
- Biologics, GLP-1s driving evolution of fill-finish manufacturing. Pharma Manufacturing. Published August 6, 2026. Accessed November 19, 2026.
Related to this article
November 19th, 2026
DISCO Pharmaceuticals will receive $40 million upfront, with up to $2.5 billion in potential milestones, to discover bispecific therapeutics for AbbVie that recognize pairs of tumor surface proteins, an approach intended to limit toxicity in healthy tissue.
November 18th, 2026
Verismo will pair Stanford's PACK-IT lentiviral technology with its KIR-CAR platform to pursue off-the-shelf, in vivo CAR T therapies for cancer.
November 18th, 2026
Visara has dosed the first patient in ASCEND, a roughly 244-patient, head-to-head phase 2b trial comparing two doses of its tetravalent VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in treatment-naïve wet AMD. The study will test dosing intervals of up to seven months and select the dose for a global phase 3 program planned as early as 2027.
November 17th, 2026
Merck's Dr Dave Maraldo explains that small-molecule platform agility and flexible conjugation capacity can help biologics manufacturing respond to research needs.
November 17th, 2026
Danish biotech Commit Biologics closed a $60 million seed round led by Ackermans & van Haaren, with AbbVie Ventures and M Ventures joining, to advance COM002, a bispecific antibody that recruits complement rather than T cells to eliminate diseased cells.
November 17th, 2026
Galinpepimut-S maintenance extended median overall survival to 24.0 vs 14.7 months in transplant-ineligible AML patients in second or later remission.
November 16th, 2026
J&J agreed to acquire Ollin Biosciences for $2.2 billion upfront, and Lilly agreed to buy Calytrix Bio for up to $1.5 billion. Novartis licensed OBI Pharma’s ADC platform, and Seawolf debuted with $100 million and a Sanofi pact.
November 13th, 2026
Merck's Dr Dave Maraldo outlines 3 principles for placing manufacturing capacity and how end-to-end ADC supply chains could shift platform thinking.
来源:BioPharm International · biopharminternational.com







